

Fabio Farinati

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3805384/fabio-farinati-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

315
papers

11,992
citations

55
h-index

97
g-index

347
ext. papers

13,621
ext. citations

5.1
avg. IF

5.99
L-index

#	Paper	IF	Citations
315	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	7
314	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. <i>Frontiers in Oncology</i> , 2022 , 12, 822507	5.3	0
313	Hemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications.. <i>Liver International</i> , 2022 ,	7.9	3
312	Mismatch repair status and gastro-oesophageal dysplasia: need for a dedicated gastrointestinal pathologist?. <i>Histopathology</i> , 2022 ,	7.3	0
311	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series.. <i>Pathology Research and Practice</i> , 2022 , 233, 153872	3.4	
310	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021 , 158, 133-143	7.5	
309	Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	4
308	Duodenal Histological Findings and Risk of Coeliac Disease in Subjects with Autoimmune Atrophic Gastritis: A Retrospective Evaluation. <i>Digestion</i> , 2021 , 102, 615-621	3.6	2
307	Circulating prostaglandin E: a novel potential prognostic biomarker in patients with hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2021 , 21, 675-682	4.9	1
306	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1078-1079	3.3	1
305	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021 , 13,	6.6	12
304	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13542	4.6	5
303	Objective Evidence of Gastro-Esophageal Reflux Disease is Rare in Patients with Autoimmune Gastritis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021 , 30, 30-36	1.4	0
302	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021 , 13,	6.6	7
301	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. <i>Cancers</i> , 2021 , 13,	6.6	6
300	Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens. <i>Pathology Research and Practice</i> , 2021 , 221, 153451	3.4	10
299	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021 , 34, 1325-1327	3	0

298	A nomogram to predict overall survival and disease-free survival after curative-intent gastrectomy for gastric cancer. <i>Updates in Surgery</i> , 2021 , 73, 1879-1890	2.9	1
297	Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Biomedicines</i> , 2021 , 9,	4.8	3
296	Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021 , 2, 45-53	0.8	1
295	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021 , 41, 396-407	7.9	7
294	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021 , 41, 585-597	25	25
293	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021 , 10, 126-136	9.1	3
292	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021 , 13,	6.6	2
291	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
290	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021 , 36, 54-61	2.8	5
289	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. <i>Digestive and Liver Disease</i> , 2021 , 53, 1011-1019	3.3	6
288	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021 , 5, 1987-2000	6	7
287	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021 , 13,	6.6	2
286	Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
285	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	2
284	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	0
283	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.. <i>Gut</i> , 2021 ,	19.2	8
282	Letter: is female sex really associated with better prognosis in hepatocellular carcinoma?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 669-670	6.1	
281	Risk of COVID-19 in celiac disease patients. <i>Autoimmunity Reviews</i> , 2020 , 19, 102639	13.6	16

280	No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy. <i>Digestive and Liver Disease</i> , 2020 , 52, 1094-1096	3.3	
279	There is much more to rely on histology than the sole endoscopy tells us. <i>Gut</i> , 2020 , 69, 1	19.2	2
278	Medical and gastroenterological education during the COVID-19 outbreak. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 447-449	24.2	10
277	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. <i>Pathology Research and Practice</i> , 2020 , 216, 152907	3.4	9
276	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020 , 72, 2206-2218	11.2	49
275	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues. <i>PLoS ONE</i> , 2020 , 15, e0244356	3.7	1
274	SARS-CoV-2 and hepatitis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 473-475	1.4	9
273	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. <i>Biomarkers in Medicine</i> , 2020 , 14, 855-867	2.3	2
272	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 188-194	3.4	8
271	PD-L1 expression in gastroesophageal dysplastic lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 151-156	5.1	10
270	Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820934315	4.7	5
269	Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. <i>Hepatology</i> , 2020 , 72, 1864-1872	11.2	108
268	The coeliac stomach: A review of the literature. <i>Digestive and Liver Disease</i> , 2020 , 52, 615-624	3.3	4
267	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and normal liver tissues 2020 , 15, e0244356		
266	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and normal liver tissues 2020 , 15, e0244356		
265	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and normal liver tissues 2020 , 15, e0244356		
264	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and normal liver tissues 2020 , 15, e0244356		
263	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. <i>British Journal of Cancer</i> , 2019 , 121, 257-263	8.7	20

262	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019 , 39, 1478-1489	7.9	27
261	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. <i>Scientific Reports</i> , 2019 , 9, 3781	4.9	9
260	Gastric fundal splenosis presenting as a stromal tumor and diagnosed by endoscopic ultrasound-guided SharkCore biopsy. <i>Endoscopy</i> , 2019 , 51, E160-E161	3.4	2
259	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 296-304	2.2	26
258	Molecular characterization of "sessile serrated" adenoma to carcinoma transition in six early colorectal cancers. <i>Pathology Research and Practice</i> , 2019 , 215, 957-962	3.4	8
257	Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. <i>Journal of Surgical Oncology</i> , 2019 , 120, 956-965	2.8	9
256	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. <i>Digestive and Liver Disease</i> , 2019 , 51, 1713-1719	3.3	11
255	Efficacy of teduglutide in a patient with Crohn's disease and short bowel syndrome on enteral nutrition: let's start to think out of the box. <i>Gastroenterology Report</i> , 2019 , 7, 459-460	3.3	0
254	Lowest Case Fatality Rate for Patients With Acute Pancreatitis Admitted in Gastroenterology Units in Veneto Region, Italy. <i>Pancreas</i> , 2019 , 48, 1175-1181	2.6	1
253	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. <i>Translational Oncology</i> , 2019 , 12, 282-291	4.9	10
252	Reply. <i>Hepatology</i> , 2019 , 69, 465-466	11.2	
251	A tricky case of pancreatic arteriovenous malformation: the role of endoscopic ultrasound in the diagnosis of this rare condition. <i>Endoscopy</i> , 2019 , 51, 195-196	3.4	3
250	Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. <i>Liver International</i> , 2018 , 38, 1770-1776	7.9	8
249	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018 , 22, 859-871	3.3	17
248	When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. <i>Digestive and Liver Disease</i> , 2018 , 50, 640-646	3.3	42
247	Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 401-406	3	4
246	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018 , 68, 1232-1244	11.2	15
245	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018 , 38, 2028-2039	7.9	5

244	MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. <i>Pathology Research and Practice</i> , 2018 , 214, 835-839	3.4	12
243	Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. <i>International Journal of Biological Markers</i> , 2018 , 33, 423-431	2.8	18
242	The "three-in-one" formulation of bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. <i>Helicobacter</i> , 2018 , 23, e12502	4.9	22
241	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. <i>World Journal of Hepatology</i> , 2018 , 10, 231-245	3.4	9
240	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018 , 67, 1784-1796	11.2	65
239	OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1621-1628	0.7	51
238	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 1157-1166	7.9	53
237	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017 , 49, 440-445	3.3	45
236	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. <i>Liver International</i> , 2017 , 37, 1184-1192	7.9	12
235	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 65-71	13.4	63
234	PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. <i>Histopathology</i> , 2017 , 71, 470-474	7.3	19
233	Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. <i>Human Pathology</i> , 2017 , 65, 62-70	3.7	48
232	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017 , 23, 1103-1112	4.5	37
231	Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 301-308	1.9	20
230	Reply. <i>Liver Transplantation</i> , 2017 , 23, 1630-1631	4.5	
229	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. <i>Histopathology</i> , 2017 , 71, 1008-1011	7.3	8
228	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 1168-1176	3.4	18
227	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 160-168	6.1	58

226	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 423-433	7.9	34
225	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017 , 37, 259-270	7.9	50
224	Capecitabine in advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016 , 48, 1260-1	3.3	4
223	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. <i>Thrombosis Research</i> , 2016 , 143, 118-21	8.2	21
222	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016 , 111, 70-7	0.7	42
221	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , 2016 , 168, 122-133	11	12
220	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016 , 13, e1002006	11.6	81
219	Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis. <i>Oncotarget</i> , 2016 , 7, 4915-243	3.4	26
218	A Liver Index and its Relationship to Indices of HCC Aggressiveness. <i>Journal of Integrative Oncology</i> , 2016 , 5,		22
217	Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 385-99	6.1	33
216	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 814-24	6.1	16
215	From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. <i>Histology and Histopathology</i> , 2016 , 31, 25-32	1.4	10
214	A new approach to the use of α -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. <i>British Journal of Cancer</i> , 2015 , 112, 69-76	8.7	49
213	Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. <i>Digestive and Liver Disease</i> , 2015 , 47, 903-12	3.3	77
212	Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1465-73	4	10
211	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015 , 21, 1250-8	4.5	9
210	Autoimmune gastritis: Pathologist's viewpoint. <i>World Journal of Gastroenterology</i> , 2015 , 21, 12179-89	5.6	106
209	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 61, 184-90	11.2	117

208	Changes in microRNA expression during disease progression in patients with chronic viral hepatitis. <i>Liver International</i> , 2015 , 35, 1324-33	7.9	11
207	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , 2015 , 35, 223-31	7.9	30
206	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. <i>Journal of Hepatology</i> , 2015 , 62, 617-24	13.4	129
205	Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. <i>World Journal of Hepatology</i> , 2015 , 7, 1097-104	3.4	11
204	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. <i>Cancer</i> , 2014 , 120, 2150-7	6.4	45
203	Letter: coffee and chronic liver damage. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 643	6.1	
202	Helicobacter pylori Infection □The Link Between Oxidative Damage, Cell Proliferation, Apoptosis, and Gastric Cancer 2014 , 1871-1891		
201	Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. <i>Seminars in Oncology</i> , 2014 , 41, 252-8	5.5	28
200	Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. <i>Seminars in Oncology</i> , 2014 , 41, 406-414	5.5	11
199	White paper of Italian Gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014 , 46, 579-89	3.3	30
198	Low alpha-fetoprotein HCC and the role of GGTP. <i>International Journal of Biological Markers</i> , 2014 , 29, e395-402	2.8	15
197	Significance of platelet and AFP levels and liver function parameters for HCC size and survival. <i>International Journal of Biological Markers</i> , 2014 , 29, e215-23	2.8	27
196	Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: an intricate pathway. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3078-86	5.6	47
195	Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. <i>Hpb</i> , 2014 , 16, 979-86	3.8	22
194	Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1637-44	4	36
193	Sorafenib use in the transplant setting. <i>Liver Transplantation</i> , 2014 , 20, 1021-8	4.5	10
192	Gastrin: from pathophysiology to cancer prevention and treatment. <i>European Journal of Cancer Prevention</i> , 2014 , 23, 258-63	2	16
191	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 61, 333-41	13.4	84

190	Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1927-33.e2	6.9	80
189	Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. <i>Digestive and Liver Disease</i> , 2013 , 45, 499-504	3.3	33
188	Advanced precancerous lesions in the liver. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2013 , 27, 269-84	2.5	42
187	Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. <i>Hepatology International</i> , 2013 , 7, 1050-7	8.8	52
186	Tryptophan hydroxylase autoantibodies as markers of a distinct autoimmune gastrointestinal component of autoimmune polyendocrine syndrome type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 704-12	5.6	33
185	Hepatocellular carcinoma in patients without cirrhosis in Italy. <i>Digestive and Liver Disease</i> , 2013 , 45, 164-9.3	3.3	31
184	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013 , 45, 712-23	3.3	128
183	The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. <i>Human Pathology</i> , 2013 , 44, 1804-10	3.7	43
182	Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation. <i>Annals of Surgical Oncology</i> , 2013 , 20 Suppl 3, S583-9	3.1	15
181	Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. <i>Liver International</i> , 2013 , 33, 1420-7	7.9	12
180	Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. <i>Liver International</i> , 2013 , 33, 1594-600	7.9	42
179	Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. <i>Future Oncology</i> , 2013 , 9, 283-94	3.6	45
178	Adequate interval for hepatocellular carcinoma surveillance. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1174	0.7	1
177	Coffee, chronic diseases and cancer. <i>European Journal of Clinical Nutrition</i> , 2013 , 67, 898	5.2	2
176	Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. <i>Hepatology</i> , 2013 , 58, 1520-1	11.2	9
175	Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study. <i>PLoS ONE</i> , 2013 , 8, e57249	3.7	21
174	Autoimmune gastritis: histology phenotype and OLGA staging. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1460-6	6.1	73
173	Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy. <i>Journal of Gastrointestinal Surgery</i> , 2012 , 16, 7-14; discussion 14-5	3.3	34

172	Letter: gastric atrophy as a precursor of gastric cancer [authors]reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 605-605	6.1	
171	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. <i>Journal of Hepatology</i> , 2012 , 56, 397-405	13.4	75
170	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. <i>Journal of Hepatology</i> , 2012 , 56, 1089-1096	13.4	48
169	TACE treatment in hepatocellular carcinoma: what should we do now?. <i>Journal of Hepatology</i> , 2012 , 57, 221-2	13.4	20
168	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. <i>Hepatology</i> , 2012 , 56, 1371-9	11.2	94
167	Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2012 , 12, 118	3	40
166	Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. <i>BMC Cancer</i> , 2012 , 12, 177	4.8	52
165	Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges. <i>Digestive Diseases</i> , 2012 , 30, 284-8	3.2	5
164	Digestive oncology: It's now or never. <i>Digestive and Liver Disease</i> , 2012 , 44, 180-1	3.3	
163	MINT31 methylation in gastric noninvasive neoplasia: potential role in the secondary prevention of gastric cancer. <i>European Journal of Cancer Prevention</i> , 2012 , 21, 442-8	2	3
162	Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1588-9; author reply 1590	0.7	5
161	Immunotherapy for gastric premalignant lesions and cancer. <i>Immunotherapy</i> , 2012 , 4, 587-99	3.8	8
160	Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. <i>American Journal of Clinical Pathology</i> , 2012 , 137, 727-32	1.9	19
159	Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 195-202 ^{2.2}	2.2	12
158	Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). <i>Annals of Surgery</i> , 2012 , 256, 788-94; discussion 794-5	7.8	38
157	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. <i>Digestive and Liver Disease</i> , 2011 , 43, 875-80	3.3	21
156	The war of the worlds: metaplastic versus nonmetaplastic atrophic gastritis. <i>Gastrointestinal Endoscopy</i> , 2011 , 73, 411-2; author reply 412-3	5.2	3
155	Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. <i>Human Pathology</i> , 2011 , 42, 1539-44	3.7	27

154	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology, The</i> , 2011 , 12, 654-62	21.7	114
153	Gastrointestinal stromal tumors: the histology report. <i>Digestive and Liver Disease</i> , 2011 , 43 Suppl 4, S304-9	3.9	16
152	Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. <i>World Journal of Gastroenterology</i> , 2011 , 17, 4596-601	5.6	81
151	Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention. <i>European Journal of Cancer Prevention</i> , 2011 , 20, 381-8	2	9
150	Interleukin 1 β and tumor necrosis factor- β polymorphisms in autoimmune gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 196	2.2	1
149	Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. <i>Liver International</i> , 2011 , 31, 192-6	7.9	5
148	Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1057-60	7.4	9
147	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1639-40; author reply 1641-2	3.5	1
146	Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. <i>Hepatology</i> , 2011 , 54, 376-7	11.2	9
145	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. <i>Cancer</i> , 2011 , 117, 125-33	6.4	34
144	Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. <i>PLoS ONE</i> , 2011 , 6, e23093	3.7	4
143	New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC. <i>Current Signal Transduction Therapy</i> , 2011 , 6, 260-266	0.8	
142	Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea. <i>Liver International</i> , 2010 , 30, 923-4; author reply 924-5	7.9	4
141	Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 493-501	6.1	27
140	Oxidative stress and inducible nitric oxide synthase induction in carcinogenesis. <i>Digestive Diseases</i> , 2010 , 28, 579-84	3.2	41
139	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. <i>Gut</i> , 2010 , 59, 387-96	19.2	121
138	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2010 , 42, 642-9	3.3	32
137	Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). <i>Digestive and Liver Disease</i> , 2010 , 42, 831-8	3.3	25

136	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. <i>Journal of Hepatology</i> , 2010 , 53, 291-7	13.4	226
135	Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. <i>Hepatology Research</i> , 2010 , 40, 153-60	5.1	6
134	Hepatic spleen nodules (HSN). <i>Scandinavian Journal of Gastroenterology</i> , 2010 , 45, 628-32	2.4	15
133	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. <i>Hepatology</i> , 2010 , 51, 165-73	11.2	75
132	Bax inhibitor-1 down-regulation in the progression of chronic liver diseases. <i>BMC Gastroenterology</i> , 2010 , 10, 35	3	12
131	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. <i>BMC Cancer</i> , 2009 , 9, 33	4.8	68
130	Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. <i>Hepatology</i> , 2009 , 50, 1162-8	11.2	76
129	Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. <i>Transplantation Proceedings</i> , 2009 , 41, 1260-3	1.1	35
128	Hepatocellular carcinoma in patients with cryptogenic cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 580-5	6.9	43
127	Gastrointestinal stromal tumors: report of an audit and review of the literature. <i>European Journal of Cancer Prevention</i> , 2009 , 18, 106-16	2	39
126	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 1212-8	2.2	37
125	Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 515-22	3.4	53
124	Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. <i>BMC Cancer</i> , 2008 , 8, 194	4.8	66
123	Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. <i>American Journal of Gastroenterology</i> , 2008 , 103, 914-21	0.7	333
122	Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. <i>European Journal of Cancer Prevention</i> , 2008 , 17, 195-200	2	65
121	Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. <i>European Journal of Cancer Prevention</i> , 2008 , 17, 438-45	2	24
120	Chemoprevention of colorectal cancer: feasibility in everyday practice?. <i>European Journal of Cancer Prevention</i> , 2008 , 17, 502-14	2	16
119	Fatal HBV-Related Liver Failure during Lamivudine Therapy in a Patient with Non-Hodgkin's Lymphoma. <i>Tumori</i> , 2008 , 94, 748-749	1.7	7

118	Oxidative DNA damage in gastric cancer: CagA status and OGG1 gene polymorphism. <i>International Journal of Cancer</i> , 2008 , 123, 51-5	7.5	56
117	TGF-beta and hepatocellular carcinoma. <i>Hepatology</i> , 2008 , 47, 1095; author reply 1095-6	11.2	
116	Micronuclei and broken eggs in human liver carcinogenesis. <i>Anticancer Research</i> , 2008 , 28, 2507-11	2.3	11
115	Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin's lymphoma. <i>Tumori</i> , 2008 , 94, 748-9	1.7	2
114	Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. <i>Molecular Cancer</i> , 2007 , 6, 17	42.1	52
113	The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results. <i>Digestive and Liver Disease</i> , 2007 , 39, 18-25	3.3	22
112	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2007 , 95, 213-20	2.8	22
111	Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 821-9	3.4	41
110	Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. <i>American Journal of Transplantation</i> , 2007 , 7, 972-81	8.7	100
109	Octreotide and hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2007 , 96, 1778-9	8.7	4
108	Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2448-57; quiz 2458	0.7	90
107	Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1022-31	0.7	47
106	Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. <i>Journal of Clinical Pathology</i> , 2007 , 60, 615-21	3.9	19
105	Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about "explosive" spread?. <i>Gut</i> , 2006 , 55, 435-6	19.2	23
104	Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1378-84	6.9	51
103	Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , 2006 , 101, 91-8	0.7	72
102	Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. <i>American Journal of Gastroenterology</i> , 2006 , 101, 524-32	0.7	323
101	Prospective validation of the Barcelona Clinic Liver Cancer staging system. <i>Journal of Hepatology</i> , 2006 , 44, 723-31	13.4	323

100	Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 1065-70	2.2	36
99	Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1495-501	6.1	13
98	Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 59, 243-9	7	40
97	Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. <i>World Journal of Gastroenterology</i> , 2006 , 12, 2065-9	5.6	27
96	Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005 , 42, 728-35	13.4	27
95	Non-invasive neoplasia of the stomach. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 1191-6	2.2	24
94	Barrett's epithelium after antireflux surgery. <i>Journal of Gastrointestinal Surgery</i> , 2005 , 9, 1253-60; discussion 1260-1	3.3	23
93	Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma. <i>Journal of Internal Medicine</i> , 2005 , 257, 367-73	10.8	6
92	Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori: scratch and win. <i>Scandinavian Journal of Gastroenterology</i> , 2005 , 40, 115-9	2.4	7
91	Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1470-6	0.7	105
90	A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. <i>Journal of Internal Medicine</i> , 2004 , 256, 529-30; author reply 531	10.8	1
89	Non-invasive diagnosis of Helicobacter pylori infection: simplified 13C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting?. <i>Clinical Biochemistry</i> , 2004 , 37, 261-7	3.5	20
88	Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. <i>Gastroenterology</i> , 2004 , 126, 382-4	13.3	24
87	Up and down regulation of apoptosis in hepatitis C virus-related liver damage. <i>Journal of Hepatology</i> , 2004 , 41, 883-5; author reply 885-6	13.4	1
86	Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. <i>Annals of Surgery</i> , 2004 , 239, 150-9	7.8	247
85	Small cell carcinoma of the major salivary glands: clinicopathologic study with emphasis on cytokeratin 20 immunoreactivity and clinical outcome. <i>American Journal of Surgical Pathology</i> , 2004 , 28, 762-70	6.7	100
84	Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia. <i>American Journal of Surgical Pathology</i> , 2004 , 28, 834-5; author reply 835	6.7	14
83	Differential effects of Helicobacter pylori eradication on oxidative DNA damage at the gastroesophageal junction and at the gastric antrum. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 1722-8	4	3

82	Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer?. <i>Helicobacter</i> , 2003 , 8, 227-34	4.9	56
81	Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease. <i>Translational Research</i> , 2003 , 141, 372-7		30
80	The mechanisms underlying hepatitis C virus genotype 3-mediated liver damage. <i>Journal of Hepatology</i> , 2003 , 39, 292-4	13.4	9
79	The long term outcome of gastric non-invasive neoplasia. <i>Gut</i> , 2003 , 52, 1111-6	19.2	128
78	Pathology and cost effectiveness of endoscopy surveillance for premalignant gastric lesions. <i>Gut</i> , 2003 , 52, 453-4	19.2	8
77	Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). <i>American Journal of Gastroenterology</i> , 2002 , 97, 734-44	0.7	255
76	Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. <i>Alcohol and Alcoholism</i> , 2002 , 37, 43-8	3.5	30
75	Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. <i>Digestive and Liver Disease</i> , 2002 , 34, 794-801	3.3	32
74	Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. <i>Current Pharmaceutical Design</i> , 2002 , 8, 1013-9	3.3	37
73	Sex hormone profile and endometrial cancer risk in primary biliary cirrhosis: a case-control study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2002 , 103, 154-7	2.4	17
72	Estrogens receptors and oxidative damage in the liver. <i>Molecular and Cellular Endocrinology</i> , 2002 , 193, 85-8	4.4	22
71	Megestrol treatment in patients with hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2001 , 85, 1606-8	7	7
70	Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2001 , 33, 217-21	3.3	24
69	DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. <i>Journal of Hepatology</i> , 2001 , 34, 587-92	13.4	92
68	HBV and HCV infections in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2001 , 20, 718-24	5.8	40
67	Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 1217-24	2.2	10
66	Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. <i>Journal of Viral Hepatitis</i> , 2001 , 8, 34-40	3.4	26
65	Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective?. <i>European Journal of Cancer Prevention</i> , 2001 , 10, 111-5	2	13

64	A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 2000 , 11, 1309-11	10.3	29
63	How should patients with hepatocellular carcinoma be staged?. <i>Cancer</i> , 2000 , 89, 2266-2273	6.4	144
62	Proteases in gastrointestinal neoplastic diseases. <i>Clinica Chimica Acta</i> , 2000 , 291, 171-87	6.2	48
61	Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. <i>Free Radical Biology and Medicine</i> , 1999 , 27, 1284-91	7.8	100
60	Hepatic and extrahepatic malignancies in primary biliary cirrhosis. <i>Hepatology</i> , 1999 , 29, 1425-8	11.2	65
59	Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis 1999 , 85, 2132-2137	11.77	
58	The role of cysteine and serine proteases in colorectal carcinoma. <i>Cancer</i> , 1999 , 86, 1135-42	6.4	87
57	A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. <i>Hepatology</i> , 1998 , 28, 751-5	11.2	1116
56	Transcatheter arterial chemoembolization in hepatocellular carcinoma. <i>Hepatology</i> , 1998 , 28, 1441-3	11.2	4
55	Oxidative DNA damage accumulation in gastric carcinogenesis. <i>Gut</i> , 1998 , 42, 351-6	19.2	215
54	Consensus statement on diet and gastric cancer. Gastric Cancer Panel. <i>European Journal of Cancer Prevention</i> , 1997 , 6, 404-7	2	4
53	Effects of N-acetyl-L-cysteine in patients with chronic atrophic gastritis and nonulcer dyspepsia: a phase III pilot study. <i>Current Therapeutic Research</i> , 1997 , 58, 724-733	2.4	1
52	Diagnosis of gastric carcinoma in Japan and western countries. <i>Lancet, The</i> , 1997 , 350, 448	40	7
51	Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. <i>Clinical and Experimental Metastasis</i> , 1997 , 15, 418-25	4.7	33
50	Cysteine and glutathione in the liver of patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1996 , 25, 123	13.4	3
49	Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 2332-9	4	61
48	Association between reactive oxygen species and disease activity in chronic hepatitis C. <i>Free Radical Biology and Medicine</i> , 1996 , 21, 291-5	7.8	178
47	Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. <i>Carcinogenesis</i> , 1996 , 17, 2581-7	4.6	32

46	Re: Helicobacter pylori and atrophic gastritis: importance of the cagA status. <i>Journal of the National Cancer Institute</i> , 1996 , 88, 762-3	9.7	8
45	Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, iron, and lipid peroxidation. <i>Hepatology</i> , 1996 , 23, 1468-75	11.2	33
44	Gastric antioxidant, nitrites, and mucosal lipoperoxidation in chronic gastritis and Helicobacter pylori infection. <i>Journal of Clinical Gastroenterology</i> , 1996 , 22, 275-81	3	75
43	Oxidative Damage in Chronic and Acute Liver Disease. 1996 , 24-32		
42	Zinc, iron, and peroxidation in liver tissue. Cumulative effects of alcohol consumption and virus-mediated damage--a preliminary report. <i>Biological Trace Element Research</i> , 1995 , 47, 193-9	4.5	17
41	Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. <i>Journal of Hepatology</i> , 1995 , 22, 449-56	13.4	320
40	Cysteine and serine proteases in gastric cancer. <i>Cancer</i> , 1995 , 76, 367-75	6.4	45
39	Gastric epithelial dysplasia. How clinicopathologic background relates to management. <i>Cancer</i> , 1995 , 76, 376-82	6.4	60
38	Effect of age on gastric acid, pepsin, pepsinogen group A and gastrin secretion in peptic ulcer patients. <i>Gerontology</i> , 1994 , 40, 253-9	5.5	21
37	Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. <i>Cancer</i> , 1994 , 73, 1127-33	6.4	30
36	A new method for detecting anti Helicobacter pylori antibodies: an analytical and clinical evaluation. <i>Journal of Clinical Laboratory Analysis</i> , 1994 , 8, 219-22	3	1
35	Hepatocellular carcinoma in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994 , 21, 315-6	13.4	54
34	Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. <i>Gastroenterology</i> , 1994 , 107, 1288-96	13.3	198
33	Thrice-yearly rhythm of duodenal ulcer disease. <i>Current Therapeutic Research</i> , 1993 , 53, 648-653	2.4	1
32	Effects of nizatidine on gastric acid and bicarbonate secretion. <i>Current Therapeutic Research</i> , 1993 , 53, 277-284	2.4	
31	Serum and salivary caffeine clearance in cirrhosis. Any role in selection for surgery and timing for transplantation?. <i>Journal of Hepatology</i> , 1993 , 18, 135-6	13.4	5
30	Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.--Interdisciplinary Group on Gastric Epithelial Dysplasia. <i>Endoscopy</i> , 1993 , 25, 261-4	3.4	76
29	Changes in parietal and mucous cell mass in the gastric mucosa of normal subjects with age: a morphometric study. <i>Gerontology</i> , 1993 , 39, 146-51	5.5	29

28	Aspartic proteinases and gastrin in the diagnosis of gastric cancer and gastric precancerous changes. <i>European Journal of Gastroenterology and Hepatology</i> , 1993 , 5, 707-712	2.2	2
27	Pathology of the gastric antrum and body associated with Helicobacter pylori infection in non-ulcerous patients: is the bacterium a promoter of intestinal metaplasia?. <i>Histopathology</i> , 1993 , 22, 9-15	7.3	58
26	Upper gastrointestinal injury caused by diquat. <i>Gastrointestinal Endoscopy</i> , 1992 , 38, 204	5.2	10
25	Anti-HCV positive hepatocellular carcinoma in cirrhosis. Prevalence, risk factors and clinical features. <i>Journal of Hepatology</i> , 1992 , 14, 183-7	13.4	34
24	Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1992 , 37, 659-62	4	53
23	Role of serum fasting gastrin in screening for hypergastrinemic syndromes in duodenal ulcer disease. <i>Clinical Biochemistry</i> , 1992 , 25, 121-4	3.5	5
22	Risk of hepatocellular carcinoma in alcoholic cirrhosis. <i>Liver</i> , 1991 , 11, 190-1		2
21	Hepatocellular carcinoma, alcohol, and cirrhosis: facts and hypotheses. <i>Digestive Diseases and Sciences</i> , 1991 , 36, 1137-42	4	26
20	CA 50 determination in body fluids: can we screen patients at risk for gastric cancer?. <i>International Journal of Cancer</i> , 1991 , 47, 7-11	7.5	12
19	Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. <i>Human Pathology</i> , 1991 , 22, 1002-8	3.7	78
18	Hormonal treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1991 , 12, 402	13.4	5
17	Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. <i>Journal of Hepatology</i> , 1990 , 11, 297-301	13.4	89
16	Diagnostic and prognostic value of the determination of the aminopropeptide of type III procollagen in patients with primary liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1990 , 5, 633-8	4	1
15	TAG-72 serum determination in early and advanced gastric cancer. <i>International Journal of Cancer</i> , 1989 , 44, 378-9	7.5	3
14	Mutagenic activity in gastric juice and urine of subjects with chronic atrophic gastritis, gastric epithelial dysplasia and gastric cancer. <i>Cancer Letters</i> , 1989 , 48, 169-75	9.9	6
13	Effects of chronic ethanol consumption on carcinogen activating and detoxifying systems in rat upper alimentary tract tissue. <i>Alcoholism: Clinical and Experimental Research</i> , 1989 , 13, 357-60	3.7	22
12	Follow-up in gastric dysplasia patients. <i>American Journal of Surgical Pathology</i> , 1989 , 13, 173-4	6.7	18
11	CA 19-9 determination in gastric juice: role in identifying gastric cancer and high risk patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 923-7		20

10	Gastric ulcer and stomach aging: pathophysiology and clinical implications. <i>Gerontology</i> , 1988 , 34, 297-303	3.5	4
9	Clinical markers of slow healing and relapsing gastric ulcer. <i>Gut</i> , 1987 , 28, 210-5	19.2	12
8	Perendoscopic gastric pH determination. Simple method for increasing accuracy in diagnosing chronic atrophic gastritis. <i>Gastrointestinal Endoscopy</i> , 1987 , 33, 293-7	5.2	8
7	The effects of chronic ethanol consumption on carcinogen metabolism and on O6-methylguanine transferase-mediated repair of alkylated DNA. <i>Alcoholism: Clinical and Experimental Research</i> , 1986 , 10, 73S-77S	3.7	54
6	Gastric juice CEA levels: importance of age and gastric mucosal damage. <i>European Journal of Cancer & Clinical Oncology</i> , 1986 , 22, 527-9		3
5	Granular cell myoblastoma of the esophagus: endoscopic diagnosis and therapy. <i>Gastrointestinal Endoscopy</i> , 1985 , 31, 22-3	5.2	3
4	Carcinoembryonic antigen in gastric juice collected during endoscopy. Value in detecting high-risk patients and gastric cancer. <i>Cancer</i> , 1983 , 52, 2334-7	6.4	18
3	Occurrence of an atypical alkaline phosphatase fraction ("biliary") in primary liver cancer. <i>Clinical Biochemistry</i> , 1983 , 16, 346-9	3.5	8
2	Is mild gastric epithelial dysplasia an indication for follow-up?. <i>Journal of Clinical Gastroenterology</i> , 1983 , 5, 307-10	3	16
1	Epithelial Dysplasia in Endoscopic Gastric Mucosal Biopsies. <i>Tumori</i> , 1981 , 67, 589-598	1.7	9